Rizzoli, R; Kraenzlin, M; Krieg, M A; Mellinghoff, H U; Lamy, O; Lippuner, K (2011). Indications to teriparatide treatment in patients with osteoporosis. Swiss medical weekly, 141, w13297. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2011.13297
Full text not available from this repository.To prevent osteoporotic fracture occurrence, a variety of treatment regimens with different mechanisms of action is available. The antiresorptive bisphosphonate drugs are currently the most commonly prescribed agents in the management of patients with osteoporosis. The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture. Teriparatide treatment reduces vertebral and non-vertebral fracture risk markedly in women and men with idiopathic osteoporosis, or with glucocorticoid-induced osteoporosis. Teriparatide should thus be considered as first line treatment for postmenopausal women and for men with severe osteoporosis.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Orthopaedic, Plastic and Hand Surgery (DOPH) > Clinic of Osteoporosis |
UniBE Contributor: |
Lippuner, Kurt |
ISSN: |
1424-7860 |
Publisher: |
EMH Schweizerischer Ärzteverlag |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:21 |
Last Modified: |
05 Dec 2022 14:06 |
Publisher DOI: |
10.4414/smw.2011.13297 |
PubMed ID: |
22057669 |
Web of Science ID: |
000296731300001 |
URI: |
https://boris.unibe.ch/id/eprint/6913 (FactScience: 211985) |
Actions (login required)
 |
Edit item |